Novartis’ RNA production facility in Schweizerhalle, Switzerland. Novartis is acquiring Avidity Biosciences for approximately $12 billion, in a deal designed to bolster the buyer’s neuroscience pipeline with three late-stage programs.…
Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication.…
10x Genomics’ facility at 5500 Stoneridge Mall Road Pleasanton, CA, one of the company’s three sites in the San Francisco suburb. 10x Genomics has joined with two licensor partners to…
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in the coming days, analysts and especially investors will keep their eyes on…
With its pipeline expanding beyond its initial focus on in vivo programming of myeloid cells, for which the company took its initial name, Myeloid Therapeutics has rebranded as Create Medicines…
If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B) saw a competitor’s bet and raised the stakes with its…